FDA approves Vyndaqel and Vyndamax capsules for the treatment of ATTR-CM
-
Last Update: 2020-06-09
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, the United StatesThe FDA(http://approved The Tafamidis Meglumine and Tafamidis capsules for the treatment of transthyroxinelobin myocardial disease (ATTR-CM)this is an FDA-approveddrug(http://for the treatment of ATTR-CMVyndaqel and Vyndamax have the same active ingredient, Tafamidis, but they are not interchangeable due to the recommended doseThe efficacy of Vyndaqel and Vyndamax in treating ATTR-CM was shown in a clinicaltrial(http://the trial included 441 patients and were randomly treated with Vyndaqel or placeboAfter an average of 30 months, the Survival Rate in the Vyndaqel Group was higher than that in the placebo group, and Vyndaqel was also shown to reduce the number of hospitalizations for cardiovascular disease (a 32% decrease)The clinical study involved a small number of patients, but no drug-related side effects were foundThe use of Tafamidis by pregnant women may cause harm to the fetusWomen taking Vyndaqel or Vyndamax should consult their doctor (http:// preventive measures if they have a pregnancy plan
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
